SCORTEN overestimates mortality in the setting of a standardized treatment protocol

被引:64
作者
Imahara, SD
Holmes, JH
Heimbach, DM
Engrav, LE
Honari, S
Klein, MB
Gibran, NS
机构
[1] Univ Washington, Dept Surg, Harborview Med Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Div Plast Surg, Harborview Med Ctr, Seattle, WA 98104 USA
关键词
D O I
10.1097/01.BCR.0000216532.71360.9B
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Toxic epidermal necrolysis (TEN) is a rare, severe, exfoliative disorder with a high mortality rate. SCORTEN is a recently developed scoring system that estimates severity and predicts mortality in patients with TEN based on seven independent clinical risk factors recorded within the first 24 hours of admission. An increasing SCORTEN level predicts a higher mortality rate. For more than 20 years, the treatment of TEN at our institution has involved the use of a standardized clinical pathway that includes removal of sloughed epidermis, dermal protection with porcine xenograft, early enteral nutrition, and critical care monitoring. We hypothesize that this standardized clinical approach will result in a lower mortality rate than predicted by SCORTEN. A retrospective review was performed on all patients treated for TEN using the standardized pathway from February 1987 to March 2004. SCORTEN was calculated in each patient. One hundred nine patients were treated for TEN during the study period. Overall observed mortality was 20% compared with a SCORTEN predicted mortality of 30%, resulting in a relative reduction in mortality of 33% (P = .011). In addition, observed probability of death was lower than predicted at all levels, except at SCORTEN score of 6 or greater. In conclusion, TEN remains a life-threatening disease with a high mortality rate. Our standardized treatment protocol results in significantly improved outcomes compared to those predicted by SCORTEN.
引用
收藏
页码:270 / 275
页数:6
相关论文
共 27 条
[1]   Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis - A prospective noncomparative study showing no benefit on mortality or progression [J].
Bachot, N ;
Revuz, J ;
Roujeau, JC .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :33-36
[2]   SCORTEN: A severity-of-illness score for toxic epidermal necrolysis [J].
Bastuji-Garin, S ;
Fouchard, N ;
Bertocchi, M ;
Roujeau, JC ;
Revuz, J ;
Wolkenstein, P .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (02) :149-153
[3]   Toxic epidermal necrolysis [J].
Becker, DS .
LANCET, 1998, 351 (9113) :1417-1420
[4]   TOXIC EPIDERMAL NECROLYSIS - AN APPROACH TO MANAGEMENT USING CRYOPRESERVED ALLOGRAFT SKIN [J].
BIRCHALL, N ;
LANGDON, R ;
CUONO, C ;
MCGUIRE, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1987, 16 (02) :368-372
[5]   TOXIC EPIDERMAL NECROLYSIS - A REVIEW AND REPORT OF THE SUCCESSFUL USE OF BIOBRANE FOR EARLY WOUND COVERAGE [J].
BRADLEY, T ;
BROWN, RE ;
KUCAN, JO ;
SMOOT, EC ;
HUSSMANN, J .
ANNALS OF PLASTIC SURGERY, 1995, 35 (02) :124-132
[6]   Toxic epidermal necrolysis: Does immunoglobulin make a difference? [J].
Brown, KM ;
Silver, GM ;
Halerz, M ;
Walaszek, P ;
Sandroni, A ;
Gamelli, RL .
JOURNAL OF BURN CARE & REHABILITATION, 2004, 25 (01) :81-88
[7]   OBSERVATIONS ON DRUG-INDUCED TOXIC EPIDERMAL NECROLYSIS IN SINGAPORE [J].
CHAN, HL .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 10 (06) :973-978
[8]   THE INCIDENCE OF ERYTHEMA MULTIFORME, STEVENS-JOHNSON SYNDROME, AND TOXIC EPIDERMAL NECROLYSIS - A POPULATION-BASED STUDY WITH PARTICULAR REFERENCE TO REACTIONS CAUSED BY DRUGS AMONG OUTPATIENTS [J].
CHAN, HL ;
STERN, RS ;
ARNDT, KA ;
LANGLOIS, J ;
JICK, SS ;
JICK, H ;
WALKER, AM .
ARCHIVES OF DERMATOLOGY, 1990, 126 (01) :43-47
[9]   Toxic epidermal necrolysis and Stevens-Johnson syndrome -: Does early withdrawal of causative drugs decrease the risk of death? [J].
Garcia-Doval, I ;
LeCleach, L ;
Bocquet, H ;
Otero, XL ;
Roujeau, JC .
ARCHIVES OF DERMATOLOGY, 2000, 136 (03) :323-327
[10]  
HEIMBACH DM, 1987, JAMA-J AM MED ASSOC, V257, P2171